{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:36Z","timestamp":1792801956796,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Heterologous prime-boost immunization regimens are a common strategy for many vaccines. DNA prime rAd5-GP boost immunization has been demonstrated to protect non-human primates against a lethal challenge of Ebola virus, a pathogen that causes fatal hemorrhagic disease in humans. This protection correlates with antibody responses and is also associated with IFN\u03b3<jats:sup>+<\/jats:sup> TNF\u03b1<jats:sup>+<\/jats:sup> double positive CD8<jats:sup>+<\/jats:sup> T-cells. In this study, we compared single DNA vs. multiple DNA prime immunizations, and short vs. long time intervals between the DNA prime and the rAd5 boost to evaluate the impact of these different prime-boost strategies on vaccine-induced humoral and cellular responses in non-human primates. We demonstrated that DNA\/rAd5 prime-boost strategies can be tailored to induce either CD4<jats:sup>+<\/jats:sup> T-cell or CD8<jats:sup>+<\/jats:sup> T-cell dominant responses while maintaining a high magnitude antibody response. Additionally, a single DNA prime immunization generated a stable memory response that could be boosted by rAd5 3 years later. These results suggest DNA\/rAd5 prime-boost provides a flexible platform that can be fine-tuned to generate desirable T-cell memory responses.<\/jats:p>","DOI":"10.3389\/fimmu.2021.627688","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T05:01:27Z","timestamp":1615266087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime\/Boost Time Interval on the Immune Response in Non-human Primates"],"prefix":"10.3389","volume":"12","author":[{"given":"Hadar","family":"Marcus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitzi M.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne A.","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Asiedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Foulds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Roederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Moliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1128\/JVI.75.5.2462-2467.2001","article-title":"Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys","volume":"75","author":"Barouch","year":"2001","journal-title":"J Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.290.5491.486","article-title":"Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination","volume":"290","author":"Barouch","year":"2000","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11563","DOI":"10.1128\/JVI.77.21.11563-11577.2003","article-title":"Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge","volume":"77","author":"Doria-Rose","year":"2003","journal-title":"J Virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization*","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12764","DOI":"10.1128\/JVI.77.23.12764-12772.2003","article-title":"Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines","volume":"77","author":"Kong","year":"2003","journal-title":"J Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6970","DOI":"10.1128\/JVI.06930-11","article-title":"A tri-clade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of HPAI H5N1 viruses","volume":"86","author":"Zhou","year":"2012","journal-title":"J Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1128\/JVI.76.12.6138-6146.2002","article-title":"Critical role for Env as well as Gag-pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime\/recombinant modified vaccinia virus Ankara vaccine","volume":"76","author":"Amara","year":"2002","journal-title":"J Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.1058915","article-title":"Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1016\/j.vaccine.2009.05.064","article-title":"A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons","volume":"27","author":"Chege","year":"2009","journal-title":"Vaccine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1128\/JVI.73.9.7524-7532.1999","article-title":"Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen","volume":"73","author":"Hanke","year":"1999","journal-title":"J Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1128\/JVI.77.18.10113-10118.2003","article-title":"Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys","volume":"77","author":"Subbramanian","year":"2003","journal-title":"J Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4049\/jimmunol.174.1.449","article-title":"Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers","volume":"174","author":"Vuola","year":"2005","journal-title":"J Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.4049\/jimmunol.1002751","article-title":"Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys","volume":"185","author":"Wilks","year":"2010","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.1128\/JVI.00645-13","article-title":"Prime\/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus","volume":"87","author":"Fiedler","year":"2013","journal-title":"J Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1128\/CVI.00637-12","article-title":"Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults","volume":"20","author":"Hayes","year":"2013","journal-title":"Clin Vaccine Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e39075","DOI":"10.1371\/journal.pone.0039075","article-title":"Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"Bakari","year":"2011","journal-title":"Vaccine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"Churchyard","year":"2011","journal-title":"PLoS ONE."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e24517","DOI":"10.1371\/journal.pone.0024517","article-title":"Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial","volume":"6","author":"Koblin","year":"2011","journal-title":"PLoS ONE."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1128\/JVI.03178-12","article-title":"Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model","volume":"87","author":"Chege","year":"2013","journal-title":"J Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/biot.201300116","article-title":"Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses","volume":"8","author":"Lin","year":"2013","journal-title":"Biotechnol J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0122835","DOI":"10.1371\/journal.pone.0122835","article-title":"Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques","volume":"10","author":"Lorin","year":"2015","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"w14465","DOI":"10.4414\/smw.2017.14465","article-title":"Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges","volume":"147","author":"Pinschewer","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","article-title":"Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity","volume":"27","author":"Gudmundsdotter","year":"2009","journal-title":"Vaccine."},{"key":"B30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1086\/650299","article-title":"A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)","volume":"201","author":"Kibuuka","year":"2010","journal-title":"J Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"15547","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag","volume":"79","author":"Casimiro","year":"2005","journal-title":"J Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates","volume":"84","author":"Geisbert","year":"2010","journal-title":"J Virol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e12873","DOI":"10.1371\/journal.pone.0012873","article-title":"Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa","volume":"5","author":"Jaoko","year":"2010","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"Koup","year":"2010","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.4049\/jimmunol.1101421","article-title":"HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable","volume":"187","author":"De Rosa","year":"2011","journal-title":"J Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1016\/j.vaccine.2011.07.048","article-title":"DNA\/Ad5 vaccination with SIV epitopes induced epitope-specific CD4 T cells, but few subdominant epitope-specific CD8 T cells","volume":"29","author":"Vojnov","year":"2011","journal-title":"Vaccine."},{"key":"B38","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.vaccine.2011.12.026","article-title":"SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses","volume":"30","author":"Lai","year":"2012","journal-title":"Vaccine."},{"key":"B40","volume-title":"Outbreaks Chronology: Ebola Virus Disease","year":"2018"},{"key":"B41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","article-title":"Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine","volume":"35","author":"Zhou","year":"2015","journal-title":"Curr Opin Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1000904","DOI":"10.1371\/journal.ppat.1000904","article-title":"Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species","volume":"6","author":"Hensley","year":"2010","journal-title":"PLoS Pathog."},{"key":"B48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-4419-5632-3_7","article-title":"Strategies and implications for prime-boost vaccination to generate memory CD8 T cells","volume":"780","author":"Nolz","year":"2011","journal-title":"Adv Exp Med Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/infdis\/jit267","article-title":"A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus","volume":"208","author":"Fournillier","year":"2013","journal-title":"J Infect Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/jit178","article-title":"DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults","volume":"208","author":"Khurana","year":"2013","journal-title":"JID."},{"key":"B52","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/infdis\/jit180","article-title":"Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect","volume":"208","author":"Ledgerwood","year":"2013","journal-title":"J Infect Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/BF03402119","article-title":"Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro","volume":"5","author":"Aoki","year":"1999","journal-title":"Mol Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jim.2006.04.007","article-title":"Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry","volume":"313","author":"Perfetto","year":"2006","journal-title":"J Immunol Methods."},{"key":"B57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.627688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T05:01:29Z","timestamp":1615266089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.627688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2021.627688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.627688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"article-number":"627688"}}